Get the latest news, insights, and market updates on DNA (Ginkgo Bioworks Holdings, Inc.). Explore the news page 4 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Why Analysts Are Divided on Ginkgo Bioworks as Its Story Shifts with New Developments
Ginkgo Bioworks Holdings has maintained its fair value price target at $12.00 per share, with only slight shifts in the underlying assessment from market analysts. The minor increase in the discount rate reflects a careful balancing of optimism about the company’s recent revenue outperformance and cost efficiency efforts, while also considering ongoing uncertainties in its growth outlook. Stay tuned to discover how you can keep track of future updates to Ginkgo Bioworks’ investment narrative... Oct 24, 2025 - $DNA
Ginkgo Bioworks in Partnership with STRM.BIO and University of British Columbia in Project to Develop In Vivo CAR Therapies Under ARPA-H's EMBODY Program
Ginkgo Bioworks (NYSE: DNA) today announced a collaboration with STRM.BIO and the University of British Columbia (UBC) as part of the Advanced Research Projects Agency for Health's (ARPA-H) Engineering of Immune Cell Inside the Body (EMBODY) program. EMBODY is led by ARPA-H Program Manager Daria Fedyukina, Ph.D. The partnership aims to develop in vivo chimeric antigen receptor (CAR) therapies for autoimmune diseases, leveraging Ginkgo's expertise in RNA construct design and immune cell engineeri Oct 23, 2025 - $DNA
Looking at the Narrative for Ginkgo Bioworks After Recent Analyst and Strategy Updates
Ginkgo Bioworks Holdings has seen its consensus analyst price target rise from $11.33 per share to $12.00 per share. This reflects a modest but noteworthy vote of confidence from the market. The upward revision comes amid shifting expectations following recent performance updates, as analysts weigh the company’s progress against lingering uncertainties. Read on to find out how you can stay ahead of ongoing changes in the stock’s evolving narrative. What Wall Street Has Been Saying Following... Oct 10, 2025 - $DNA
Ginkgo Bioworks Holdings Stock Scores RS Rating Upgrade
Ginkgo Bioworks Holdings stock had its Relative Strength (RS) Rating upgraded from 88 to 92 Tuesday. Is Ginkgo Bioworks Holdings Stock A Buy? Ginkgo Bioworks Holdings stock recently retook its 50-day moving line and is trying to complete a cup without handle with a 15.48 buy point. Sep 30, 2025 - $DNA
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple